Pyxis Oncology (PYXS) AI Stock Analysis

• Market Cap: $73.72M
• Dividend Yield: N/A
• Average Volume (3M): 612.41K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.48
• Revenue Growth: N/A
• EPS Growth: 30.51%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.35
• Shares Outstanding: 61,947,666
• 10 Day Avg. Volume: 370,785
• 30 Day Avg. Volume: 612,409
• PEG Ratio: 0.03
• Price to Book (P/B): 0.70
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.22
• Enterprise Value/Market Cap: 1.07
• Enterprise Value/Revenue: 1.27
• Enterprise Value/Gross Profit: 70.74
• Enterprise Value/Ebitda: -0.28
• 1Y Price Target: $6.67
• Price Target Upside: 470.09% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 47 Neutral
• Price Target: ―

Pyxis Oncology's score reflects ongoing financial challenges with significant cash burn and unprofitability. While there are positive developments with the strategic focus on its lead candidate, technical indicators suggest caution. Valuation remains unattractive due to negative earnings. The company's future hinges on successful execution of its strategic initiatives.

Positive Factors

Clinical Activity

MICVO has shown promising clinical activity as a standalone treatment, particularly in patients with recurrent/metastatic head and neck squamous cell carcinoma, and is generally well-tolerated, reducing common side effects seen with other treatments.

Clinical Trials

New preclinical data support broad anti-tumor activity, particularly in head and neck cancer, validating Pyxis’ development focus.

Strategic Moves

The assumption of CMO duties by CEO Lara Sullivan is seen as a strategic move to enhance focus and efficiency in clinical execution.

Negative Factors

Clinical Differentiation

The head-and-neck cancer results are difficult to differentiate with only modest activity in other solid tumor histologies.

Financial Performance

Net loss of $21.2 million, or a loss of $0.35 per share, was comparable to the projected loss, indicating financial challenges.

Investor Sentiment

PYXS’s persistent underperformance and negative EV evidently reflects continued investor skepticism of micvo’s opportunity in SCCHN.

Pyxis Oncology Business Overview & Revenue Model

Company Description

Pyxis Oncology, Inc. (PYXS) is a biopharmaceutical company focused on developing novel antibody-drug conjugates (ADCs) and immuno-oncology therapeutics for the treatment of cancer. The company operates within the healthcare sector, primarily targeting oncology as its core field. Pyxis Oncology aims to address unmet medical needs by leveraging its proprietary platforms to discover and develop innovative therapies that improve patient outcomes.

How the Company Makes Money

Pyxis Oncology generates revenue through a combination of research and development collaborations, licensing agreements, and potential milestone payments from strategic partnerships with other pharmaceutical companies. The company's business model is largely reliant on advancing its pipeline of oncology therapeutics through clinical trials, securing regulatory approvals, and ultimately commercializing these products either independently or through collaborators. Revenue streams may also include upfront payments and royalties from licensing its technologies and products to other companies in the pharmaceutical industry. The success of Pyxis Oncology's revenue model depends on its ability to successfully develop and market its therapeutic candidates, as well as forming beneficial partnerships that enhance its product offerings and market reach.

Pyxis Oncology Financial Statement Overview

Summary

Pyxis Oncology is at a critical growth stage, with efforts to generate revenue, yet profitability remains elusive. Financial stability is supported by cash reserves, but negative cash flows and equity challenges pose significant risks. The company may need strategic actions to achieve sustainable financial health.

Income Statement

Pyxis Oncology's income statement shows a recent introduction of revenue, yet the company remains unprofitable with persistent negative net income. The negative EBIT and EBITDA margins indicate ongoing operational challenges, although gross profit margin has improved due to revenue generation.

Balance Sheet

The balance sheet reveals high equity levels but also significant liabilities, resulting in a moderate debt-to-equity ratio. The company has a substantial cash position, yet the negative stockholder's equity in earlier years and recent reduction in equity suggest financial vulnerabilities.

Cash Flow

Cash flow analysis indicates negative free cash flow and operating cash flow, highlighting cash burn issues. There is some improvement in financing cash flow, yet the reliance on external funding is evident. The free cash flow to net income ratio remains unfavorable.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.15M	0.00	0.00	0.00	0.00
Gross Profit	15.67M	-2.00M	-1.84M	-1.25M	-444.00K
EBITDA	-65.51M	-78.49M	-122.77M	-69.07M	-12.43M
Net Income	-77.33M	-73.79M	-117.95M	-81.54M	-12.76M
Balance Sheet
Total Assets	157.18M	173.73M	211.38M	280.02M	10.15M
Cash, Cash Equivalents and Short-Term Investments	126.93M	119.30M	179.29M	274.74M	8.08M
Total Debt	20.20M	21.33M	18.92M	165.00K	780.00K
Total Liabilities	36.43M	48.02M	50.55M	18.71M	25.80M
Stockholders Equity	120.75M	125.70M	160.82M	261.31M	-15.64M
Cash Flow
Free Cash Flow	-57.91M	-77.44M	-95.73M	-35.87M	-11.57M
Operating Cash Flow	-57.67M	-70.71M	-89.33M	-35.33M	-10.08M
Investing Cash Flow	8.15M	-104.85M	-6.40M	-590.00K	-1.48M
Financing Cash Flow	59.33M	5.93M	183.00K	304.04M	35.00K

Pyxis Oncology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.17
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PYXS, the sentiment is Negative. The current price of 1.17 is above the 20-day moving average (MA) of 1.17, below the 50-day MA of 1.19, and below the 200-day MA of 1.78, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.33 is Neutral, neither overbought nor oversold. The STOCH value of 59.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PYXS.

Pyxis Oncology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MGX	57 Neutral	$78.50M	―	-31.93%	―	-4.22%	18.67%
AVTX	55 Neutral	$51.97M	―	678.24%	―	-69.59%	―
Sector *	52 Neutral	$7.47B	-0.04	-63.86%	2.34%	16.17%	0.25%
PYXS	47 Neutral	$73.72M	―	-66.30%	―	―	30.51%
ANRO	42 Neutral	$71.74M	―	-38.04%	―	―	―
CABA	39 Underperform	$152.00M	―	-73.85%	―	―	-40.59%

Pyxis Oncology Corporate Events

Pyxis Oncology Highlights Strategic Focus on Lead Candidate

On March 24, 2025, Pyxis Oncology updated its corporate presentation, highlighting its focus on advancing its lead product candidate, micvotabart pelidotin, for treating recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The company is positioning itself as a differentiated ADC company with a strong cash runway and multiple clinical data catalysts expected in 2025 and 2026. This strategic focus aims to address significant unmet needs in the R/M HNSCC treatment landscape, potentially enhancing Pyxis Oncology’s position in the oncology sector.

Pyxis Oncology Announces CMO Resignation and New Trials

On March 18, 2025, Pyxis Oncology announced the resignation of Ken Kobayashi, M.D., as Chief Medical Officer, with Lara S. Sullivan, M.D., assuming the role alongside her current duties as President and CEO. The company also reported positive preliminary data from its Phase 1 trial of micvotabart pelidotin, receiving Fast Track Designation from the FDA for treating certain head and neck cancers, and initiated further clinical trials, including a combination study with Merck’s KEYTRUDA®. Pyxis Oncology has streamlined its operations, reducing its workforce by 20% to focus on advancing the MICVO clinical program, and expects its cash runway to extend into the second half of 2026.